口服微粒化黄体酮与阴道黄体酮在新鲜胚胎移植周期中黄体期支持的比较:一项多中心、随机、非劣效性试验
该多中心随机非劣效性试验纳入1310例首次或第二次IVF的不孕女性,比较口服微粒化黄体酮400 mg/天、600 mg/天与阴道黄体酮90 mg/天用于黄体期支持。意向性分析显示,口服400 mg/天组持续妊娠率非劣效于阴道黄体酮组(35.3% vs 38.0%,绝对差-2.6%,95%CI -9.0%至3.8%,非劣效性检验P=0.010),而600 mg/天组非劣效性证据不足。
要点
- 口服微粒化黄体酮400 mg/天组持续妊娠率非劣效于阴道黄体酮90 mg/天组。
- 口服微粒化黄体酮600 mg/天组与阴道黄体酮组相比,非劣效性证据不足。
- 各组间活产率未见统计学显著差异。
核心结论
- 口服微粒化黄体酮400 mg/天组的持续妊娠率非劣效于阴道黄体酮凝胶90 mg/天组。
- 口服微粒化黄体酮600 mg/天组与阴道黄体酮凝胶组相比,非劣效性证据不足。
研究设计与样本
- 该研究为在中国8个学术生育中心开展的非劣效性随机试验,时间从2018年11月至2019年11月,随访于2021年4月完成。
- 共纳入1310例接受首次或第二次IVF周期的不孕女性,在hCG给药日随机分为三组:口服微粒化黄体酮400 mg/天(n=430)、口服微粒化黄体酮600 mg/天(n=440)或阴道黄体酮90 mg/天(n=440)。
- 黄体期支持从取卵日开始,持续至妊娠11-12周,主要结局为持续妊娠率。
主要发现
- 在意向性分析中,口服微粒化黄体酮400 mg/天组持续妊娠率为35.3%,阴道黄体酮凝胶组为38.0%,绝对差为-2.6%(95%CI -9.0%至3.8%),非劣效性检验P=0.010。
- 口服微粒化黄体酮600 mg/天组持续妊娠率为31.6%,阴道黄体酮凝胶组为38.0%,绝对差为-6.4%(95%CI -12.6%至-0.1%),非劣效性检验P=0.130,非劣效性证据不足。
- 各组间活产率未见统计学显著差异。
临床怎么用
- 作者认为,对于不愿接受阴道给药途径的患者,口服微粒化黄体酮400 mg/天可能作为阴道黄体酮凝胶的替代选择。
- 作者指出,更高剂量口服微粒化黄体酮是否与较差的妊娠率或较高的早产率相关,需进一步研究。
局限性
- 本试验的主要结局是持续妊娠率,但活产率可能具有更大的临床意义。
- 尽管结果未显示活产率差异,但需更大样本量的进一步试验予以确认。
- 本研究中最终卵母细胞成熟由hCG触发,结论可能不适用于使用促性腺激素释放激素激动剂触发的周期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does oral micronized progesterone result in a non-inferior ongoing pregnancy rate compared to vaginal progesterone gel as luteal phase support (LPS) in fresh embryo transfer cycles? SUMMARY ANSWER: The ongoing pregnancy rate in the group administered oral micronized progesterone 400 mg per day was non-inferior to that in the group administered vaginal progesterone gel 90 mg per day. WHAT IS KNOWN ALREADY: LPS is an integrated component of fresh IVF, for which an optimal treatment regimen is still lacking. The high cost and administration route of the commonly used vaginal progesterone make it less acceptable than oral micronized progesterone; however, the efficacy of oral micronized progesterone is unclear owing to concerns regarding its low bioavailability after the hepatic first pass. STUDY DESIGN, SIZE, DURATION: This non-inferiority randomized trial was conducted in eight academic fertility centers in China from November 2018 to November 2019. The follow-up was completed in April 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 1310 infertile women who underwent their first or second IVF cycles were enrolled. On the day of hCG administration, the patients were randomly assigned to one of three groups for LPS: oral micronized progesterone 400 mg/day (n = 430), oral micronized progesterone 600 mg/day (n = 440) or vaginal progesterone 90 mg/day (n = 440). LPS was started on the day of oocyte retrieval and continued till 11-12 weeks of gestation. The primary outcome was the rate of ongoing pregnancy. MAIN RESULTS AND THE ROLE OF CHANCE: In the intention-to-treat analysis, the rate of ongoing pregnancy in the oral micronized progesterone 400 mg/day group was non-inferior to that of the vaginal progesterone gel group [35.3% versus 38.0%, absolute difference (AD): -2.6%; 95% CI: -9.0% to 3.8%, P-value for non-inferiority test: 0.010]. There was insufficient evidence to support the non-inferiority in the rate of ongoing pregnancy between the oral micronized progesterone 600 mg/day group and the vaginal progesterone gel group (31.6% versus 38.0%, AD: -6.4%; 95% CI: -12.6% to -0.1%, P-value for non-inferiority test: 0.130). In addition, we did not observe a statistically significant difference in the rate of live births between the groups. LIMITATIONS, REASONS FOR CAUTION: The primary outcome of our trial was the ongoing pregnancy rate; however, the live birth rate may be of greater clinical interest. Although the results did not show a difference in the rate of live births, they should be confirmed by further trials with larger sample sizes. In addition, in this study, final oocyte maturation was triggered by hCG, and the findings may not be extrapolatable to cycles with gonadotropin-releasing hormone agonist triggers. WIDER IMPLICATIONS OF THE FINDINGS: Oral micronized progesterone 400 mg/day may be an alternative to vaginal progesterone gel in patients reluctant to accept the vaginal route of administration. However, whether a higher dose of oral micronized progesterone is associated with a poorer pregnancy rate or a higher rate of preterm delivery warrants further investigation. STUDY FUNDING/COMPETING INTEREST(S): This research was supported by a grant from the National Natural Science Foundation of China (82071718). None of the authors have any conflicts of interest to declare. TRIAL REGISTRATION NUMBER: This trial was registered at the Chinese Clinical Trial Registry (http://www.chictr.org.cn/) with the number ChiCTR1800015958. TRIAL REGISTRATION DATE: May 2018. DATE OF FIRST PATIENT’S ENROLMENT: November 2018.
引用
- Niu Y, Liu H, Li X, et al. Oral micronized progesterone versus vaginal progesterone for luteal phase support in fresh embryo transfer cycles: a multicenter, randomized, non-inferiority trial. Hum Reprod. 2023. PMID: 37982413. doi:10.1093/humrep/deac266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。